Renaissance Technologies LLC Sells 64,942 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Renaissance Technologies LLC cut its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 55.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,900 shares of the company’s stock after selling 64,942 shares during the quarter. Renaissance Technologies LLC owned 0.07% of Trevi Therapeutics worth $155,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in shares of Trevi Therapeutics by 217.6% during the second quarter. Dimensional Fund Advisors LP now owns 72,210 shares of the company’s stock valued at $215,000 after purchasing an additional 49,475 shares during the period. American Century Companies Inc. grew its stake in shares of Trevi Therapeutics by 17.1% in the second quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock worth $161,000 after purchasing an additional 7,902 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Trevi Therapeutics by 44.8% in the second quarter. Rhumbline Advisers now owns 75,218 shares of the company’s stock worth $224,000 after purchasing an additional 23,263 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Trevi Therapeutics by 38.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 178,511 shares of the company’s stock valued at $532,000 after purchasing an additional 49,884 shares during the period. Finally, Rosalind Advisors Inc. raised its position in Trevi Therapeutics by 50.3% during the 2nd quarter. Rosalind Advisors Inc. now owns 1,391,577 shares of the company’s stock valued at $4,147,000 after purchasing an additional 465,561 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

TRVI has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a research report on Friday, October 4th. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, August 19th. Raymond James started coverage on shares of Trevi Therapeutics in a report on Friday, August 30th. They issued an “outperform” rating and a $9.00 price objective for the company. Leerink Partners started coverage on shares of Trevi Therapeutics in a research note on Monday, September 9th. They set an “outperform” rating and a $7.00 target price on the stock. Finally, Leerink Partnrs raised shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $7.43.

Trevi Therapeutics Price Performance

Shares of NASDAQ TRVI opened at $3.12 on Monday. Trevi Therapeutics, Inc. has a 1 year low of $0.97 and a 1 year high of $4.00. The firm has a 50-day moving average of $3.03 and a 200 day moving average of $2.89. The stock has a market cap of $226.48 million, a P/E ratio of -8.00 and a beta of 0.97.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). During the same period in the previous year, the company earned ($0.07) earnings per share. Research analysts expect that Trevi Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Insider Transactions at Trevi Therapeutics

In other news, CEO Jennifer L. Good sold 10,981 shares of Trevi Therapeutics stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total value of $33,162.62. Following the completion of the transaction, the chief executive officer now owns 213,313 shares of the company’s stock, valued at $644,205.26. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Jennifer L. Good sold 10,981 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total transaction of $33,162.62. Following the sale, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at $644,205.26. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Thomas Sciascia sold 18,660 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $2.76, for a total value of $51,501.60. Following the completion of the transaction, the insider now directly owns 220,315 shares of the company’s stock, valued at approximately $608,069.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,355 shares of company stock valued at $116,663. Insiders own 24.37% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.